As part of its expansion and commitment to ensuring the highest standards of pharmaceutical quality, MB Therapeutics is delighted to announce the joining of Manon Perez as the future Responsible Pharmacist and Chief Quality Officer (CQO).

Expertise in Toxicology and Pharmacovigilance

With her background in industrial pharmacy and specialization in toxicology, risk assessment, and vigilance (Master THERV), Manon Perez possesses solid expertise in risk management, pharmacovigilance, and pharmaceutical quality systems.

Her experience has provided her with a deep understanding of regulatory challenges, risk management, and pharmaceutical quality requirements, particularly in strictly regulated environments such as those of Good Manufacturing Practices. Her experience and skills in quality management make her a key asset for MB Therapeutics.

A Strategic Mission within MB Therapeutics

Joining MB Therapeutics means, above all, becoming part of an innovative company driven by strong values and a clear ambition. It is an exciting challenge where quality excellence and regulatory rigor play a central role in ensuring patient safety.

 Manon Perez, Quality Director

As the future Responsible Pharmacist and CQO, Manon will play a central role in establishing and reinforcing the company's quality standards, overseeing regulatory aspects, quality control, and compliance with the requirements of health agencies such as the ANSM and ANVISA

MB Therapeutics continues its development

With this new appointment, MB Therapeutics reaffirms its commitment to guaranteeing pharmaceutical inks compliant with the strictest requirements. This evolution takes place in a key phase of the company's development, marked by the opening of its new premises and its future pharmaceutical establishment dedicated to the production of GMP-certified pharmaceutical inks.

The arrival of Manon Perez at the quality department further strengthens the commitment of MB Therapeutics to delivering innovative, safe, and personalized solutions to patients.